ArticlemAbs
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.Dermatology and therapy · 2026Review
- Human papillomavirus 18 E6-specific Affibody inhibits cervical cancer cell proliferation and induces apoptosis.Applied microbiology and biotechnology · 2026Article
- EfficientInternational journal of molecular sciences · 2026Article
- Clinical value of IL-17-targeted intervention in tissue injury repair: from bidirectional mechanisms to therapeutic strategies.Frontiers in immunology · 2026Review
- Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report.Frontiers in medicine · 2026Article
- Preclinical Positron Emission Tomography Imaging of B7-H3 Expression Using Affibody Molecules Labeled with Gallium-68.ACS pharmacology & translational science · 2025Article
- Deep sequencing combined with high-throughput screening enables efficient development of a pH-dependent high-affinity binding domain targeting HER3.Protein science : a publication of the Protein Society · 2025Article
- The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects.Rheumatology and therapy · 2025Review
- An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma.International journal of molecular sciences · 2025Article
- Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review.American journal of clinical dermatology · 2025Review
- Structure-based computational design of antibody mimetics: challenges and perspectives.FEBS open bio · 2025Review
- Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants.Frontiers in immunology · 2025Article
- Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- The management of adult and paediatric uveitis for rheumatologists.Nature reviews. Rheumatology · 2024Review
- Evaluation of a novelEuropean journal of nuclear medicine and molecular imaging · 2024Article
- [Variants of biotechnological drugs in dermatology : Status quo and future].Dermatologie (Heidelberg, Germany) · 2024Article
- Surface-engineered bacteria in drug development.Microbial biotechnology · 2024Review
- Article
- Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.Biomedicines · 2024Review
- Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation.EJNMMI radiopharmacy and chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatment with monoclonal antibodies (mAbs) against IL-17A provides an improvement in the Psoriasis Area and Severity Index compared to conventional systemic agents. In this study, the Affibody
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.